Cell regeneration, without the associated cost or ethical issues.
By providing access to exosome-based regenerative medicine tools with a broad range of applications, Endexome is bringing the power of cell regeneration – in the form of bioactive exosomes – to clinical applications without the associated cost or ethical issues that can often be linked with regenerative medicine technologies.
Endexome commercialises cutting edge technologies developed by one of its partners, CK Cell Technologies. This direct translation from lab-based Research & Development activities to the clinic and beyond makes innovative regenerative medicine solutions available to all Australians. Read more.
Endexome is contributing to the growing global regenerative medicine industry with its exosome-based therapies. We promise to make available exosome-based treatment applications, which mimic the power of cell based therapy but without the associated cost or ethical issues. Read more.
Endexome has a proprietary process for the extraction and production of safe, stable and highly active exosomes at scale. The final product (Endexome-Exo) is bioactive, immuno-evasive and lyophilised for easy supply. In this form, the exosomes can be delivered as treatment tools via injection, nasal spray, cream, bandages or micro-needling. Read more.
Executive Management
Advisory Board
Founder and
Chief Scientific Officer
Founder and
Chief Medical Officer
%20(1)%20(1).jpeg)
Dr Sangeeta Aditya
Head of Business & Operations
Bioengineering Advisor
Milestones
Scroll to learn about our company’s journey
